Upadacitinib for Refractory Paediatric Atopic Dermatitis: A Real-World Study on Effectiveness and Safety in Dupilumab Nonresponders. Gannon RM, Chow T. Pediatrics 2025;156.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Gannon RM, Chow T. Upadacitinib for Refractory Paediatric Atopic Dermatitis: A Real-World Study on Effectiveness and Safety in Dupilumab Nonresponders. Pediatrics 2025;156.
PMID: 41320034